How Technology Is Changing the Way We Look at Health Data, & How Patients Are Critical to Its Success
Pete Knox represents The Life Raft Group and GIST patients at ISPOR’s 2019 European Conference, held November 2nd-6th in Copenhagen, Denmark.
Making the Most of the Holiday Season
The holiday season is quickly approaching and the stress of the holidays can bring up mixed feelings for many people. When you are struggling with a cancer diagnosis such as GIST, the holidays can be an extra-challenging time of year.
The LRG Partners with GIST Survivor on Facebook
GIST Survivor is a private group and only members can see who is in the group and what is posted. The group is for GIST survivors who are searching for a cure and living well along the way. Currently 1,235 people are members of the group and this number is increasing daily.
Are YOU Seeing a GIST Specialist?
When diagnosed with any disease, it's important to see a specialist who will have the proper experience to guide you to an effective treatment protocol. This LRG survey queried LRG members about physicians, the physician's ability to answer their questions, and who recommended their GIST specialist in order to get a snapshot of patients' satisfaction with their with their care.
Increasing Survival without Borders
The Life Raft Group is pleased to announce the official establishment of our Regional Patient Registry, a partnership with Latin America, which will collect medical history and treatment information from more than 600 GIST patients who are represented by Fundación GIST Mexico, Fundación GIST Chile, and Pontificia Universidad Católica de Chile.
Sisters of the Heart for a Cure
Wendy Williams became a member of The Life Raft Group in August of 2017. She was introduced to the LRG by one of her closest friends, Michelle MacLea, whose son Connor was diagnosed with SDH-deficient GIST in 2017.
NDA for Ripretinib Submitted to FDA for Treatment of GIST
Breaking news in Targeted Oncology online today - A New Drug Application (NDA) for Ripretinib (DCC-2618) was submitted to FDA for treatment of GIST, by Deciphera.
First-Line Imatinib More Effective Than Widely Believed – LRG Science
The latest issue of LRG Science is titled, "First-Line Imatinib More Effective Than Widely Believed - LRG Science - Treatment for Resistant GIST - Improved, but Still Very Far to Go." In this issue, the LRG Real World Evidence team analyzes data from our Patient Registry in order to evaluate the efficacy of imatinib as a first-line treatment in GIST. Subscribe to LRG Science by emailing mgarland@liferaftgroup.org with the subject line SUBSCRIBE LRG SCIENCE.
Medicamentos Para GIST: Existentes y Nuevos
Esta presentación cuenta la historia de los medicamentos para GIST, de cómo llagamos a donde hoy estamos, y como miramos hacia donde vamos en el futuro. Entrega información de cada medicamento que ha sido [...]
Current and Emerging Medications For GIST
Pete Knox's presentation on current and emerging medications for GIST.